We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Abbott Showcases Next-Generation Alinity Family of Systems at AACC 2020 Virtual Event

By LabMedica International staff writers
Posted on 15 Dec 2020
Image: Alinity Family of Systems (Photo courtesy of Abbott)
Image: Alinity Family of Systems (Photo courtesy of Abbott)
Abbott (Lake Forest, IL, USA) showcased leading-edge technology at its virtual booth at 2020 AACC Annual Scientific Meeting with demonstrations of the company’s innovative systems, automation and informatics.

At the all virtual 2020 AACC held on December 13-17, Abbott demonstrated its next-generation Alinity family of systems across key laboratory disciplines designed to simplify diagnostics and help deliver results that drive better patient outcomes. Attendees to Abbott’s virtual booth experienced the company’s Alinity ci-series integrated clinical chemistry and immunoassay system, the Alinity h-series integrated hematology system and the Alinity m molecular system.

The Alinity series helps to easily adapt to the unpredictability of changing laboratory volume with scalable systems and multiple track connectivity options across Alinity platforms. The flexible, scalable systems allow easy addition of modules as lab volume grows over time, without having to replace any system. And with open automation and IT connectivity options such as Instrument Manager and AlinIQ BIS, a personalized solution can be designed for the entire laboratory. All this helps labs respond to the changing needs of the market and the community.

Alinity leverages powerful technology to redefine and improve operational productivity in the laboratory. Alinity allows users to more efficiently and effectively address limited space and increasing demand in their laboratory. Alinity has been designed to maximize the throughput in a more compact footprint. Additionally, Alinity allows staff more walkaway time, so they can focus on other critical tasks.

Alinity helps labs continually provide consistent, high-quality service and results through error-proof design elements and proven technology that minimize the frustration of repeat testing, system downtime, and medical errors. Additionally, labs can rely on Abbott’s high-quality assays with proven technology harmonized to CLSI guidelines, ensuring clear performance parameter definitions. And with predictive system monitoring through AlinIQ Always On, Abbott’s professional services can proactively monitor the health of the systems and help labs avoid unexpected downtime.


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Drug Test Kit
DrugCheck 3000

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
PURITAN MEDICAL